Cited by 449Liver Disease Diagnosis and TreatmentChronic Kidney Disease and DiabetesAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.

NAFLD as a driver of chronic kidney disease

Byrne, Christopher D., Targher, Giovanni·2020·Journal of Hepatology

DOI 10.1016/j.jhep.2020.01.013

Open this paper in CoChat — free account

Abstract

Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are worldwide public health problems, affecting up to 25-30% (NAFLD), and up to 10-15% (CKD) of the general population. Recently, it has also been established that there is a strong association between NAFLD and CKD, regardless of the presence of potential confounding diseases such as obesity, hypertension and type 2 diabetes. Since NAFLD and CKD are both common diseases that often occur alongside other metabolic conditions, such as type 2 diabetes or metabolic syndrome, elucidating the relative impact of NAFLD on the risk of incident CKD presents a substantial challenge for investigators working in this research field. A growing body of epidemiological evidence suggests that NAFLD is an independent risk factor for CKD and recent evidence also suggests that associated factors such as metabolic syndrome, dysbiosis, unhealthy diets, platelet activation and processes associated with ageing could also contribute mechanisms linking NAFLD and CKD. This narrative review provides an overview of the literature on: a) the evidence for an association and causal link between NAFLD and CKD and b) the underlying mechanisms by which NAFLD (and factors strongly linked with NAFLD) may increase the risk of developing CKD.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.01.013

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, R. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,320
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
NAFLD: A multisystem disease
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,162
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245

Show all 144 references

Sorted by citations

Items 301–400 of 449

Regional insights into the relationship between metabolic associated steatotic liver disease and chronic kidney disease: a socioeconomic perspective on disease correlation
Bai, J., Zhang, L., Zhang, M., Hao, Y., Yi, Z., & Zhou, Y. (2025) · BMC Public Health · doi:10.1186/s12889-025-22188-3 · Cited by 5
Obesity drives the link between liver fat and depression: Cross‐sectional and prospective investigations
Feng, Q., Izzi‐Engbeaya, C. N., Manousou, P., & Woodward, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16562 · Cited by 2
Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses
Zhong, L., Wu, C., Li, Y., Zeng, Q., Lai, L., Chen, S., & Tang, S. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221083508 · Cited by 3
Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice
Villani, R., Magnati, G. P., Tuccari, G., Sangineto, M., Romano, A. D., Cassano, T., & Serviddio, G. (2022) · Ultrasound · doi:10.1177/1742271x221122585 · Cited by 3
The liver-kidney axis: Is serum leptin a potential link in non-alcoholic fatty liver disease-associated chronic kidney disease?
Canbakan, M., Bakkaloğlu, O. K., Atay, K., Köroğlu, E., Tuncer, M. M., Canbakan, B., & Şentürk, H. (2023) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2023.01.001 · Cited by 3
Sex-specific association of body mass index and fatty liver index with prevalence of renal hyperfiltration: a cross sectional study using Japanese health check-up data
Kitazawa, A., & Fukuda, Y. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03137-x · Cited by 3
Chronic kidney disease and non-alcoholic fatty liver disease - new pathogenetic links
Krasner, Y. A., Осипенко, М. Ф., Холин, С. И., & Litvinova, N. V. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-212-4-140-144 · Cited by 3
Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults
Shi, A., Deng, J., Ma, J., Yang, L., Tantai, X., Wang, Q., Chang, D., Wang, J., Guo, X., Lu, X., et al. (2023) · Obesity Facts · doi:10.1159/000533626 · Cited by 3
Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Zhang, C., Sui, Y., Liu, S., & Yang, M. J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00029 · Cited by 3
Clinical correlates of CT imaging-derived phenotypes among lean and overweight patients with hepatic steatosis
Song, I., Thompson, E. W., Verma, A., MacLean, M. T., Duda, J., Elahi, A., Tran, R., Raghupathy, P., Swago, S., Hazim, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-49470-x · Cited by 3
Extra Virgin Olive Oil Reduces the Risk of Non-Alcoholic Fatty Liver Disease in Females but Not in Males: Results from the NUTRIHEP Cohort
Donghia, R., Tatoli, R., Campanella, A., Losurdo, G., Leo, A. D., Pergola, G. D., Bonfiglio, C., & Giannelli, G. (2024) · Nutrients · doi:10.3390/nu16193234 · Cited by 3
A Metabolomics-Based Approach for Diagnosing NAFLD and Identifying Its Pre-Condition Along the Potential Disease Spectrum
Nojima, M., Kimura, T., Aoki, Y., Fujimoto, H., Hayashi, K., Ohtake, J., Kimura-Asami, M., Suzuki, K., Urayama, K. Y., Matsuura, M., et al. (2025) · Livers · doi:10.3390/livers5010012 · Cited by 3
What Is the Role of Sex Differences in Obesity-Associated Chronic Kidney Disease?
Sandino, J., González-García, C., Hernández-Velasco, P., & Morales, E. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000546354 · Cited by 3
Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic Steatohepatitis
Reja, M., Patel, R., Pioppo, L., Tawadros, A., Bhurwal, A., Marino, D., & Rustgi, V. K. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001389 · Cited by 3
Early Kidney Dysfunction in Metabolic-Associated Fatty Liver Disease: Is Transient Elastography Useful as a Screening Method?
Freitas, M., Silva, V. M., Xavier, S. A., Magalhães, J. T., Marinho, C. M. M., & Cotter, J. B. (2021) · Digestive Diseases · doi:10.1159/000514811 · Cited by 3
Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease
Moein, H. R., Arteaga, E. J., & Sarkar, S. (2022) · Clinical Liver Disease · doi:10.1002/cld.1191 · Cited by 3
Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
Lian, K., Fan, Q., Sheng, S., Zhang, K., Sun, X., Kan, C., Pan, R., & Guo, Z. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00189-3 · Cited by 2
Advances in understanding the mechanism of noncoding RNA (ncRNA)-mediated regulation of macrophage polarization in NAFLD
Ge, C., Yuan, Y., Li, X., Zhang, J., Ling, J., Zheng, X., Wu, Y., Huang, X., Yang, P., Liu, X., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117372 · Cited by 2
Beyond the association: towards an integrated hepato–renal approach
Pérez-Escobar, J., Velázquez-Silva, R. I., Carpinteyro‐Espín, P., & Gasca-Aldama, J. C. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102155 · Cited by 2
MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors
Saad, Z. M., Keryakos, H. K. H., Hassanin, H. A., Higazi, M. M., Sayed, M. M., Ismail, D. E., & Abdelhalim, S. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336568 · Cited by 2
Incidence of Chronic Kidney Disease According to Steatotic Liver Disease and Its Subclassifications: A Longitudinal Cohort Study
Kim, A., Kang, D., Choi, S. C., Sinn, D. H., Jang, H. R., & Gwak, G. (2025) · Gut and Liver · doi:10.5009/gnl250157 · Cited by 2
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes
Miyatani, Y., Ogawa, A., Sempokuya, T., Tran, C. T., James, D., Seto, T. B., Shikuma, C., & Kuwada, S. K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1739137 · Cited by 2
Association of cardiovascular-kidney-metabolic syndrome stages with MASLD prevalence and liver fibrosis severity: evidence from traditional and machine learning approaches
Zheng, Y., Li, T., Guo, S., & Song, J. (2026) · European journal of medical research · doi:10.1186/s40001-026-04037-0 · Cited by 2
MASLD Beyond the Liver: A Systemic Driver of Cardiovascular, Renal, and Oncologic Risk
Liguori, A., Calvez, V., Petrucci, L., Termite, F., Tomasello, L., Sciarra, A., Varca, S., Gasbarrini, A., Pompili, M., & Miele, L. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00732-y · Cited by 3
Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis
Soares, A. O., Loli, D. A. C., de Carvalho, G. R., Delfino, V. D. A., & Bignardi, P. R. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10059-0 · Cited by 2
Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
Crespo, J., Iruzubieta, P., de Vega, T., & Calleja, J. L. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107536 · Cited by 2
ASSOCIATION OF LOW GFR AND NON-ALCOHOLIC HEPATOSTEATOSIS ON FIBROSCAN OF LIVER
Baqai, K., Mahmud, M., Anwar, M., Samejo, S. A., Hussain, N., & Wasim, A. (2023) · Journal of Ayub Medical College Abbottabad · doi:10.55519/jamc-01-11051 · Cited by 2
Nonalcoholic fatty liver disease: A risk factor for chronic kidney disease
Carvalho, K. S. D., Daltro, C., Rocha, R., & Cotrim, H. P. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101122 · Cited by 2
Unmetabolized folic acid and organ fibrosis: Are they nefarious partners?
Goldstein, M. R., & Mascitelli, L. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111323 · Cited by 2
Risk Evaluation of Progression of Proteinuria and Renal Decline Based on a Novel Subgroup Classification in Chinese Patients with Type 2 Diabetes
Wang, K., Qian, Q., Bian, C., Sheng, P., Zhu, L., Teng, S., & An, X. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01667-7 · Cited by 2
RENAL INJURY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH OBESITY
Carvalho, K. S. D., de Sousa, C. D., Daltro, C., & Cotrim, H. P. (2025) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612025-008 · Cited by 2
Challenges in measuring renal function in liver cirrhosis: are there implications in clinical practice?
Carvão, J., Carvão, J., Pereira, V., & Jasmins, L. (2020) · PubMed · Cited by 2
Co-Existent Hypertension with Diabetes Mellitus Exacerbates Renal Dysfunctions
Obore, E. A., Asiwe, J. N., Iyawe, V. I., & Edo, A. E. (2022) · Biology Medicine & Natural Product Chemistry · doi:10.14421/biomedich.2022.112.145-150 · Cited by 3
Urinary neutrophil gelatinase‐associated lipocalin: A novel biomarker for predicting chronic kidney disease in patients with nonalcoholic fatty liver disease
Navadurong, H., Prasoppokakorn, T., Srisawat, N., Chaiteerakij, R., Komolmit, P., Tangkijvanich, P., & Treeprasertsuk, S. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.32 · Cited by 2
The correlation of metabolic and renal biomarkers with vitamin D status in postmenopausal women
Klisic, A. N., Vujacic, I. R., Kostadinović, J., & Ninić, A. (2023) · Journal of Medical Biochemistry · doi:10.5937/jomb0-41044 · Cited by 2
Association of nonalcoholic fatty liver disease with acute cholangitis: a nationwide propensity-matched analysis from the United States
Patel, P., Inayat, F., Ali, H., Afzal, A., Taj, S., Rehman, A. U., Hussain, N., Ishtiaq, R., Nawaz, G., Afzal, M. S., et al. (2023) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2023.2231721 · Cited by 2
Specific patterns and potential risk factors to predict 3-year risk of death among non-cancer patients with advanced chronic kidney disease by machine learning
Chang, T., Chen, Y.-D., Lu, H. H., Wu, J. L., Mak, K., & Yu, C.-S. (2024) · Medicine · doi:10.1097/md.0000000000037112 · Cited by 2
Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study
Shima, H., Tashiro, M., Inoue, T., Okada, K., Okamoto, T., Wariishi, S., Doi, T., & Minakuchi, J. (2024) · Cureus · doi:10.7759/cureus.57777 · Cited by 2
Role of patatin-like phospholipase domain-containing 3 gene for decreasing kidney function in recently diagnosed diabetes mellitus
Zaharia, O., Straßburger, K., Knebel, B., Binsch, C., Kupriyanova, Y., Möser, C., Bódis, K. B., Prystupa, K., Yurchenko, I., Cardenas, D. M. M., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103137 · Cited by 2
Agrimonia pilosa Extract Alleviates CDAHFD-Induced Non-Alcoholic Steatohepatitis and Fibrosis in MicePreprint
Park, S., Jo, M., Ryu, Y., Seo, M.-G., Lee, J. W., Kim, Y. H., Kim, Y.-D., & Park, J. (2023) · Preprints.org · doi:10.20944/preprints202309.0608.v1 · Cited by 2
The effect of non-alcoholic fatty liver disease on the functional state of the kidneys in patients with chronic heart failure
Стаценко, М. Е., Туркина, С. В., Fabritskaya, S. V., Шилина, Н. Н., Титаренко, М. Н., Kosivtsova, M. A., Ryndina, Y. A., & Radzabova, A. A. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-194-10-35-42 · Cited by 1
Probiotics and the gut-liver axis
Amedei, A., Gitto, S., Campani, C., & Marra, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85170-1.00003-8 · Cited by 1
Analysis of the Epidemiological Features and Pathological Types of Chronic Kidney Disease
张, 琪. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123185 · Cited by 1
Metabolic Dysfunction-associated Steatotic Liver Disease Increases the Risk of Primary Open-Angle Glaucoma
Chen, C., Qi, J., Zhang, K., Meng, J., Lu, Y., Wang, F., & Zhu, X. (2025) · Ophthalmology Glaucoma · doi:10.1016/j.ogla.2024.12.007 · Cited by 1
Association between Noninvasive Liver Biomarkers and Graft Outcomes in Kidney Transplantation Recipients
Lee, J., Baek, C. H., Kim, S. B., & Jung, C. (2025) · American Journal of Nephrology · doi:10.1159/000542914 · Cited by 1
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges
Piatto, D., Biasio, D. D., Cesaro, F. G., Forcina, G., Frattolillo, V., Colucci, A., Lamberti, F., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113911 · Cited by 1
Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease
Wang, Z., Wu, H., Fu, H., Xue, Y., Shen, L., Zhu, J., Zhu, Z., Yu, X., Zhou, R., & Shang, W. (2025) · Endocrine Connections · doi:10.1530/ec-25-0285 · Cited by 1
End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease
Ko, H. Y., Hong, B., Bea, S., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112921 · Cited by 2
Physical activity and the risk of cardiovascular disease, cirrhosis, cancer and mortality among individuals with MASLD: a prospective cohort study
Xu, S., Xiao, Y., Xu, C., Zeng, X., Zhao, L., Li, T., Jiang, D., Na, R., & Chen, H. (2025) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2025-002702 · Cited by 1
Agrimonia pilosa Extract Alleviates CDAHFD-Induced Non-Alcoholic Steatohepatitis and Fibrosis in Mice
Park, S., Jo, M.-J., Ryu, Y., Seo, M.-G., Lee, J. W., Kim, Y. H., Kim, Y., & Park, S. (2025) · Nutrients · doi:10.3390/nu18010042 · Cited by 2
Comparison of transient elastography and shear wave elastography as a routine diagnostic method for assessing liver fibrosis in Indian participants with liver steatosis
GUPTA, M., Kumar, D., Chandra, K. P., & Maheshwari, A. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01611-w · Cited by 1
Multi-omics analysis reveals gut microbiota remodeling and lipid metabolism regulation during the treatment of nonalcoholic fatty liver disease with Yindan Pinggan capsule
Hou, J., Li, S., Zhang, F., Xiao, H., Li, X., & Yang, H. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01351-x · Cited by 1
Targeting SLC7A11 to Suppress PI3K/AKT Signaling: Dapagliflozin ameliorates MASH and associated renal injury via ferroptosis inhibition and Liver-Kidney axis regulation
Qiu, H., Tan, X., Sheng, Q., Yang, N., Jiang, C. M., & Wang, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118096 · Cited by 2
Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging
Heo, J. H., Sung, D.-E., Kang, J., Zhou, X., Zheng, M., & Sung, K. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104817 · Cited by 1
Extracellular vesicles from steatotic hepatocytes promote endothelial dysfunction and atherogenesis via miR-30b-5p/ELOVL5 axis
Rhee, M., Lee, J., Jung, C. W., Yang, J., Choi, W. G., You, Y., Park, H., Lee, E. Y., Lee, E. Y., Kwon, S. W., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.031 · Cited by 2
Adipokine Profile in Non-alcoholic Fatty Liver Disease
Trisha, C., Prabhat Kumar, N., Ch, N., Chinnapaka, M., & Thota, R. K. (2026) · Cureus · doi:10.7759/cureus.112017 · Cited by 1
Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye
Sümbül, H. E., Kırık, A., Yaylacı, S., Oral, A., Serın, S. O., Issever, K., Koca, N., Aydin, A., Demir, İ., Gözel, N., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11139-8 · Cited by 1
Relationship between anemia and biochemical parameters of mineral bone disorders in chronic kidney disease patients
Sayed, M. A., Ismail, H., Saad, A., & Farouk, M. (2022) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.21608/aimj.2022.130263.1888 · Cited by 1
Fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3–5: A follow‐up study of NHANES III
Huang, J., Zhang, M., Wu, Y., Wang, M.-F., Zhu, Y., & Lin, S. (2022) · Hepatology Communications · doi:10.1002/hep4.2086 · Cited by 1
The Relationship Between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease.
Byrne, C. D. (2022) · PubMed Central · Cited by 1
The Entanglement between Metabolic Associated Non- Alcoholic Fatty liver Disease and Chronic Kidney Disease Progression is more than just a Strong Correlation. A Narrative Review
Nasreldin, M. A. (2022) · International Journal of Clinical Nephrology · doi:10.31579/2834-5142/036 · Cited by 1
Diabesity and the Kidney
Elrggal, M. E., Elkeraie, A. F., Carriazo, S. M., Sawaf, H., Khor, S. Y., Elkeraie, Y., Haddad, I. R., Moustafa, K., & Hassanein, M. M. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070009 · Cited by 1
Non-alcoholic fatty liver disease, cardiovascular system and kidney function in young adults
Чулков, В. С., Pankova, E. D., Krasnopeeva, N., & Сергеевич, Ч. В. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-3-15-21 · Cited by 1
Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.11.010 · Cited by 1
Rosemary (Rosmarinus officinalis L.) improves biochemical outcomes in diabetes mellitus: a systematic review and meta-analysis of animal studies
Oliveira, V. M., Silveira, L. R., Bunnel, K. T., Domingueti, C. P., Baldoni, A. O., Baldoni, N. R., & do Couto, R. O. (2024) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-024-00742-5 · Cited by 3
Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients
Shen, C., Zhang, J., Tian, Z., Cao, J., Jiao, Y., Wang, B., Feng, S., Luo, Z., Zhang, Q., Deng, Y., et al. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2280-3742 · Cited by 1
Epidemiology of Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus and Effects of Antiglycemic Therapy on Liver Fibrosis: A Retrospective Study
Butt, M. I., Puri, G., Berkman, K., Ryder, S. J., Knowles, J., Shahzad, M. A., Malik, M. A., Shalev, N., & Sexton, J. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem937 · Cited by 1
The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population
Huang, Y., Zhou, Y., Wang, Y., Chi, J., Lv, W., Wang, Y., & Chen, Y. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1815-7559 · Cited by 1
Renal Artery Resistive Index and Estimated Glomerular Filtration Rate in Patients with Non-alcoholic Fatty Liver Disease
Aksu, Y., Uslu, A. U., Tarhan, G., & Tiryaki, Ş. (2022) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405618666220516123519 · Cited by 1
Metabolisches Syndrom und Nierenkrankheiten
Ganz, M. J., Bender, S. T., Gross, C., Bose, K., Mertens, P. R., & Scurt, F. G. (2022) · Die Nephrologie · doi:10.1007/s11560-022-00595-6 · Cited by 1
Bioinformatics analysis of differentially expressed genes in non alcoholic fatty liver disease using next generation sequencing dataPreprint
Vastrad, B. M., & Vastrad, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472893 · Cited by 1
Norcholic acid: a novel biomarker of early kidney injury in patients with metabolic dysfunction-associated fatty liver diseasePreprint
Sun, D., Xu, C., Chen, W., Yuan, F., Targher, G., Lonardo, A., Zhao, J., Liu, A., Su, M., Shi, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2789347/v1 · Cited by 1
Diabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Correction of endothelial dysfunction in patients with type 2 diabetes mellitus, diabetic kidney disease and non-alcoholic steatohepatitis
Kotsiubiichuk, Z. Y., Антонів, А. А., Каньовська, Л. В., & Mandryk, O. Y. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.1.2024.1350 · Cited by 1
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
Wang, J., Fan, T. T., Zhang, S., Wu, C., & Huang, R. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17922 · Cited by 1
Novel genetic insights into the roles of amino acids in metabolic dysfunction-associated steatotic liver diseasePreprint
Liu, J., Chen, Y., Qian, J., Cui, R., Demirkan, A., & Zheng, Y. (2024) · medRxiv · doi:10.1101/2024.04.09.24305556 · Cited by 1
Screening for Chronic Renal Insufficiency Should Focus on People with Diabetes, Insulin Resistance or Advanced Fibrosis in MASLDPreprint
Yang, T., Yang, B., Yin, J., Hou, C., & Wang, Q. (2024) · Research Square · doi:10.21203/rs.3.rs-4324844/v1 · Cited by 1
Stratified Burden of MASLD in Cardiovascular-Kidney-Metabolic syndrome: Stage-Dependent Prevalence and Insulin Resistance-Driven Cardiovascular MortalityPreprint
Li, Z., Yang, Q., Xiao, M., Zhang, X., Deng, Y., Liu, H., Liu, X., Sun, Y., & Xiao, X. (2025) · medRxiv · doi:10.1101/2025.04.07.25325431 · Cited by 1
Ectopic fat depots as a factor of cardiovascular risk in patients with nonalcoholic fatty liver disease
Стаценко, М. Е., Туркина, С. В., Андреевна, Т. И., & Gorbacheva, E. E. (2021) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2020-98-11-12-759-765
Short-Term Weight Loss Decreased the Risk of Chronic Kidney Disease in Incident NAFLD Participants: A Prospective CohortPreprint
Hu, S., Li, X., Sun, Y., Wu, S., Lan, Y., Chen, S., wang, Y., Liao, W., wang, X., Zhang, D., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3920905
The Negative Association Between Non-alcoholic Fatty Liver Disease Severity and Gouty Nephropathy in a Non-diabetic Gouty Population: A Cross-Sectional StudyPreprint
Zhou, Y., Wang, Y., Chi, J., Lv, W., Xing, M., Wang, Y., & Chen, Y. (2020) · doi:10.21203/rs.3.rs-60574/v1
A novel method for chatter control and improvement of surface finish in end milling
Amin, A. K. M. N., & Sulaiman, S. A. (2012)
Frequency of Metabolic Associated Fatty Liver Disease among Chronic Kidney Disease Patients in Upper Egypt
Bazeed, S. E. S., Fayed, H. M., Hashim, A. A., Abdelhady, O. R. A., & Abdel-Monem, S. A. (2022) · SVU-International Journal of Medical Sciences · doi:10.21608/svuijm.2022.128484.1299
Modern aspects of pathogenesis of comorbidity of non-alcoholic fatty liver disease and hypertension in the presence or absence of chronic kidney disease.
Prosolenko, K., Lapshyna, K., & Ryabuha, V. V. (2022) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2022.01.055
Factors Associated with Risk of NAFLD and Progression in Multiethnic Asians. A Latent Class and Machine Learning AnalysisPreprint
Ng, C. H., Nah, B. K. Y., Kaewdech, A., Bwa, A. H., Mak, L., Kulkarni, A. V., & Muthiah, M. D. (2022) · Research Square · doi:10.21203/rs.3.rs-1968295/v1
Alcohol Consumption and Nonalcoholic Fatty Liver Disease: Effects on Chronic Kidney DiseasePreprint
Zheng, T., Wang, X., Kamili, K., Luo, C., Hu, Y. B., Wang, D., Wang, B., Gao, P., & Tian, G. (2022) · Research Square · doi:10.21203/rs.3.rs-2154933/v1
Predictors of Renal Damage in non diabetic Metabolic Dysfunction associated Fatty Liver Disease (MAFLD) Patients: Role of Tumor Necrosis Factor αPreprint
Younis, M. A., Zaghloul, A., Hashim, M. S., Ali, T. M., Mohammed, A. H., & Ahmed, N. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2431824/v1
RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
Heeba, G. H., Abolnaga, M., & Othman, E. M. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.301257
Non-alcoholic Fatty Liver Disease as risk factors for Chronic Kidney Disease: A Bidirectional Mendelian Randomization StudyPreprint
Chen, M., Nian, Q., & Zheng, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3036719/v1
Identification and Analysis of Pivotal Genes in Type 2 Diabetes Mellitus Combined With Non-Alcoholic Fatty Liver DiseasePreprint
Xiao, S., Yang, Y., & Wang, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3160837/v1
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease
Cojocariu, C., Popa, C. A., Muzica, C. M., Stanciu, C., Cuciureanu, T., & Trifan, A. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_15
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Clinical Evidence and a Mechanistic Review
屈, 飏. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381788
Picroside II alleviated non-alcoholic fatty liver disease via the AMPK-Nrf2 pathway.Preprint
Zhao, L., Chen, X., Li, Z., Wei, Y., Shen, B., Wang, Q., Cheng, J., & Feng, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3692295/v1
Vascular endothelial cell-specific overexpression of CNP did not improve liver fibrosis in HFFCD-induced NASH, but did improve renal lesions
Ensho, T., Hino, J., Ueda, Y., Miyazato, M., & Iwakura, H. (2023) · Peptides · doi:10.1016/j.peptides.2023.171146
Assessment of Renal Insufficiency among Non-Hypertensive and Non-Diabetic Adults with Non-Alcoholic Fatty Liver Disease
Hassan, E. A. (2021) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2021.17.555958
Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular complications: what do they have in common?
As, A., & Туркина, С. В. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-87-98
STEATOSIC LIVER DISEASE AND CARDIOVASCULAR DISEASES: ASSOCIATION, PROGNOSIS AND TREATMENT
Ткаченко, Т. В., & Tomashkevych, H. (2023) · Modern medicine pharmacy and psychological health · doi:10.32689/2663-0672-2023-4-9
Metabolic comorbidities, endocrine—Diabetes, polycystic ovarian syndrome, thyroid dysfunction
Yang, R., & Fan, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00004-2
La sfida della prevenzione in medicina interna: a call for action | The challenge of prevention in internal medicine: a call for action
Dentali, F., & Rotunno, S. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.q.2024.4
Correlation Between Serum Transaminase Levels and Estimated Glomerular Filtration Rate After Living-Donor Kidney Transplantation
Kim, H., & Kim, Y.-S. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.02.031

Authors: Byrne, C. D., & Targher, G.
Affiliations: University Hospital Southampton NHS Foundation Trust (GB)
University of Verona (IT)
Corresponding author: Byrne, Christopher D.
Targher, Giovanni
ORCID: Byrne, Christopher D.
Targher, Giovanni
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2020-04
Volume: 72
Issue: 4
Pages: 785-801
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2020.01.013
OpenAlex: W3006576880
Cited by: 449
References: 144
Citations by year: 2026: 45 · 2025: 72 · 2024: 76 · 2023: 85 · 2022: 79 · 2021: 57 · 2020: 34
FWCI: 9.30
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (acceptedVersion)
Funders: NIHR Bristol Biomedical Research Centre (IS-BRC-20004)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: non-alcoholic fatty liver disease, chronic kidney disease, CKD risk factors, metabolic syndrome, dysbiosis, platelet activation, aging, type 2 diabetes, obesity, hypertension, unhealthy diet, pathophysiological mechanisms
MeSH terms: Adolescent, Adult, Aging, Child, Diabetes Mellitus, Type 2, Diet, Female, Humans, Male, Middle Aged, Obesity, Risk Factors, Platelet Activation, Comorbidity, Prevalence, Metabolic Syndrome, Renal Insufficiency, Chronic, Young Adult, Dysbiosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NAFLD as a driver of chronic kidney disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks